Policy

Global preventive AIDS vaccine R&D investment totaled US$818 million in 2013, with the public sector providing US$666 million (81%), the philanthropic sector providing US$121 million (15%), and the commercial sector contributing US$31 million (4%). The 2013 total investment represents a decrease of US$29 million (4%) below global preventive AIDS vaccine R&D investment in 2012.

Continue Reading

IAVI and the Futures Institute, with support from the U.S. Agency for International Development (USAID), have developed a model to estimate the impact that preventive AIDS vaccines could have on HIV epidemics at both national and global levels. Such projections can assist policymakers, vaccine developers, advocates and funders make informed decisions and effective resource allocations. Such modeling has shown that a vaccine could avert millions of new HIV infections and AIDS-related deaths, and will be needed to end AIDS even if ambitious targets for access to HIV prevention, treatment and care are reached before a vaccine is introduced.

Continue Reading